Regeneron stock price forecast: consolidation likely as REGN faces resistance below recent highs

Traders Union
All News
Companies
Regeneron up 0.93% today at 756.48

Highlights

REGN consolidates near weekly highs, encountering short- and medium-term resistance while maintaining a strong long-term uptrend.
Momentum indicators are mixed, showing neutral to overbought intraday sentiment and weak directional strength, suggesting limited upward momentum.
Baseline expectation for the coming week is a sideways or modestly bullish range between $734 and $770, with a breakout above $770 needed to challenge annual highs.

REGN is trading at $756.48, which positions it below the MA-20 ($759.32) and MA-50 ($763.75), but well above the long-term MA-200 ($656.79). This configuration indicates residual short- to medium-term resistance from sellers while the broader uptrend remains intact, anchored by stronger long-term support. The Ichimoku Kijun on D1 stands at $761.33, currently acting as immediate resistance. Near-term support lies at the MA-100 ($749.40) and key support is at the MA-200 ($656.79). Immediate resistance is seen at the Ichimoku Kijun ($761.33), with key resistance at the MA-50 ($763.75).

Momentum indicators on D1 are mixed. MACD signals a sell, while ADX shows weak directionality, indicating lackluster momentum. RSI is neutral at 49.26, and CCI is also neutral, but BBP is in overbought territory, signaling buyers remain dominant intraday. The weekly performance shows REGN has risen $23.97 (3.27%) since the previous close at $732.51, trading at the very top of its weekly range—suggesting approach to resistance. Weekly volatility stands at 4.64%. The session is marked by consolidation near highs, with oscillators and trend indicators showing visible divergence and some loss of upward power.

For the coming week, the expected trading range is $734 to $770, keeping REGN well within its 52-week band of $476.49 to $820.37. Based on W1 momentum (RSI, ADX, MACD, and MA-50), there is a very high probability (more than 80%) of sideways or upside movement, making a decline much less likely. The baseline scenario is price holding in a sideways corridor between $734 and $770. The bullish scenario entails a breakout above $763–$770 resistance, opening a path closer to the yearly highs. The bearish scenario would see a breach below $749, testing support toward $734, but current long-term signals make this outcome unlikely.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that the FDA approved Regeneron Pharmaceuticals' treatment for allergic fungal rhinosinusitis in patients aged 6 and older. This latest development introduces a new factor for investors to monitor, with the prevailing scenario now hinging on the company’s ability to translate recent regulatory successes into sustained revenue growth.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.